Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

The older population consisting of persons aged 65 years or older is the fastest-growing
population group and also the major consumer of pharmaceutical products. Due to the …

Extensive studies have been conducted to predict in vivo metabolic clearance from in vitro
human liver metabolism parameters (ie, in vitro–in vivo extrapolation (IVIVE)) with little …

Physiologically based pharmacokinetic (PBPK) models have been proposed as a tool for
more accurate individual pharmacokinetic (PK) predictions and model‐informed precision …

Quantitative systems pharmacology holds the promises of integrating results from laboratory
animals or in vitro human systems into the design of human pharmacokinetic …

The fresh or cryopreserved human umbilical cord (HUC) and its byproducts, such as cells
and extracts, have different uses in tissue regeneration. Defining what HUC byproduct is …

Many chemicals in day-to-day and industrial usage have the ability to cross the blood–brain
barrier and develop neurotoxicity in humans. There are numerous in vitro, in vivo …

Rationale: Liver cirrhosis is known to affect drug pharmacokinetics, but the functional
assessment of the underlying pathophysiological alterations in drug metabolism is difficult …

Quantitative systems pharmacology (QSP) is an emerging discipline uniting bottom-up
approaches from systems biology with top-down approaches from Pharmacometrics. QSP …

The metabolization and excretion of drugs in the liver are spatially heterogeneous
processes. This is due to the spatial variability of physiological processes at different length …